Application of ethyl benzoylacetate in aspect of destroying activity of mature biofilm

By using the oil-in-water emulsion of ethyl benzoylacetate and Tween 80 in the body, the extracellular polysaccharide and protein content of bacterial biological membrane is reduced, the membrane structure is destroyed, and the problem of poor antibacterial treatment in the body is solved, and safety is achieved Efficient bacterial membrane damage and antibacterial enhancement.

CN119033749APending Publication Date: 2024-11-29SOUTHWEST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410857100.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to safely and efficiently destroy the mature biological membranes of bacteria in the body, resulting in limited antibacterial treatment effects, especially the increased difficulty in treating drug-resistant Klebsiella pneumoniae.

Method used

Ethyl benzoyl acetate and Tween 80 are used in a specific oil-in-water emulsion to reduce the content of extracellular polysaccharides and proteins in the mature biological membrane of bacteria, resulting in the collapse of the three-dimensional structure of the biological membrane, thereby destroying the membrane.

Benefits of technology

At sub-anti-bacterial concentrations, ethyl benzoylacetate significantly reduces the extracellular macromolecule level of the biomass, improves the antibacterial therapeutic effect, and can be used in combination with antibiotics to enhance the antibacterial effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033749A_ABST
    Figure CN119033749A_ABST
Patent Text Reader

Abstract

The invention relates to an application of ethyl benzoylacetate in destroying the activity of a mature biofilm, and belongs to the technical field of biological medicines. According to the invention, ethyl benzoylacetate is used as an anti-biofilm compound, has the capability of efficiently destroying a mature biofilm under the sub-inhibitory concentration, and can significantly reduce the macromolecular levels of extracellular proteins, extracellular polysaccharides and the like in an extracellular matrix. In addition, the ethyl benzoylacetate reduces the macromolecule level in the extracellular matrix of the mature biofilm, the three-dimensional structure of the biofilm collapses, and therefore the biofilm infection treatment effect is remarkably improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to the application of ethyl benzoyl acetate in destroying the activity of mature biofilm. Background Art

[0002] Klebsiella pneumoniae is a zoonotic conditional pathogenic Gram-negative bacillus that mainly colonizes the upper respiratory tract and gastrointestinal tract of pigs, sheep, cattle and poultry. It is widely present in veterinary clinics. In recent years, with the emergence of drug-resistant Klebsiella pneumoniae, it has posed a serious threat to public health and safety. At the same time, the infection rate of livestock and poultry has increased and the difficulty of treatment has increased. However, the formation of biofilm on the surface of Klebsiella pneumoniae is considered by many scholars to be an important reason for the drug resistance of the bacterium.

[0003] Biofilm refers to a bacterial group attached to the surface of living or inanimate objects and wrapped in bacterial extracellular matrix. Its formation is a dynamic process, including four stages: planktonic bacteria adhere to the surface of cells or objects, aggregate to form microcolonies, differentiate to form mature membranes, and then separate and release bacteria in the membrane from the biofilm, and then a new round of biofilm formation will be repeated. In the mature biofilm stage, bacteria will secrete various biomacromolecules such as proteins, polysaccharides, DNA, RNA, etc. to form an extracellular matrix. Various macromolecules in the extracellular matrix aggregate with each other to form an intricate three-dimensional network structure, which seriously affects the effective penetration of therapeutic drugs. The minimum inhibitory concentration of bacteria in biofilms is often 10 to 1000 times that of planktonic bacteria. The eradication of biofilms can significantly improve the effect of antibacterial treatment, reduce veterinary drug residues in livestock and poultry and by-products under the "low cost and high safety" mode, bring considerable economic value to the breeding industry, and have good clinical transformation application potential.

[0004] At present, the mechanism of action and effect of biofilm inhibitors mainly involve the fields of inhibiting initial bacterial adhesion, interfering with biofilm formation, regulating quorum sensing, and destroying mature biofilms. However, for the destruction of mature biofilms, current attempts have been made to use compounds with bactericidal effects such as surfactants and metal chelates, and these two types of compounds are feasible for sterilization of skin, environment or equipment in vitro, but are too toxic for sterilization or enhanced sterilization in vivo in humans or animals, so they are not suitable for in vivo administration routes (oral or injection). At present, ethyl benzoyl acetate is usually used as a food-grade flavor, such as the flavor of fruit wines such as brandy, or as an intermediate of flavonoid drugs, and there is no report that ethyl benzoyl acetate destroys mature biofilms at sub-inhibitory concentrations.

[0005] Therefore, it is urgent to design or screen anti-biofilm compounds that can effectively interfere with or eradicate biofilms. Summary of the invention

[0006] In view of this, the purpose of the present invention is to provide an application of ethyl benzoylacetate in destroying the activity of mature biofilms, so as to solve the problem that the extracellular matrix of mature biofilms forms an intricate three-dimensional network structure that affects the antibacterial and antimicrobial therapeutic effect, reduce the amount of extracellular polysaccharides and extracellular proteins in the extracellular matrix of biofilms, cause the three-dimensional structure of bacterial biofilms to collapse, and achieve a safe and efficient mature biofilm destruction effect.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] 1. Application of ethyl benzoyl acetate in destroying the activity of mature biofilm.

[0009] Preferably, in the application, ethyl benzoyl acetate, Tween 80 and sterile water are used to prepare an oil-in-water emulsion.

[0010] Further preferably, the volume ratio of ethyl benzoyl acetate, Tween 80 and sterile water in the oil-in-water emulsion is 86:100-200:1714-1814.

[0011] Preferably, in the application, ethyl benzoylacetate reduces the content of extracellular polysaccharides and extracellular proteins in the extracellular matrix of mature bacterial biofilms, thereby causing the collapse of the three-dimensional structure of the bacterial biofilm.

[0012] Preferably, the mature biofilm includes but is not limited to any one of Klebsiella pneumoniae, Escherichia coli or Salmonella.

[0013] Preferably, the application also includes combined application with antibacterial drugs.

[0014] Preferably, the antibacterial drugs include any one or more of tetracycline, meropenem or ceftriaxone sodium.

[0015] The beneficial effects of the present invention are as follows: the present invention discloses the application of ethyl benzoylacetate in destroying the activity of mature biofilms, and ethyl benzoylacetate is used as an anti-biofilm compound, which has the ability to efficiently destroy mature biofilms at sub-inhibitory concentrations, and can significantly reduce the levels of macromolecules such as extracellular proteins and extracellular polysaccharides in the extracellular matrix. In addition, ethyl benzoylacetate reduces the level of macromolecules in the extracellular matrix of mature biofilms, causing the collapse of the three-dimensional structure of the biofilm, thereby significantly improving the therapeutic effect of biofilm infection.

[0016] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0018] Figure 1 The appearance diagram of the ethyl benzoyl acetate emulsion prepared in Example 1, wherein A is the appearance diagram of the solvent and B is the appearance diagram of the ethyl benzoyl acetate emulsion;

[0019] Figure 2 The drug sensitivity test results of ethyl benzoyl acetate in Example 2;

[0020] Figure 3 The crystal violet test result of ethyl benzoyl acetate in Example 2;

[0021] Figure 4 The crystal violet staining results of ethyl benzoyl acetate treated for different time periods in Example 2;

[0022] Figure 5 The visualization results of the biofilm before and after the action of ethyl benzoyl acetate in Example 3, wherein A is a scanning electron microscope image and B is a laser confocal microscope plane image stained with SYTO9 / PI;

[0023] Figure 6 The viscosity curves of the biofilm before and after the action of ethyl benzoyl acetate in Example 3 are shown;

[0024] Figure 7 The results of the effect of ethyl benzoylacetate on the extracellular proteins of biofilm in Example 4, wherein A is the standard protein curve and B is the measurement result;

[0025] Figure 8 The results of the effect of ethyl benzoyl acetate on the extracellular polysaccharide of biofilm in Example 4, wherein A is the standard glucose curve and B is the measurement result;

[0026] Fig. 9 These are the results of the effect of ethyl benzoyl acetate on the extracellular DNA of biofilms in Example 4.

[0027] Fig.10 These are the FICI results of the combined use of ethyl benzoylacetate and meropenem in the 8 bacterial strains tested by the chessboard method in Example 5.

[0028] Fig.11 The results of resazurin in Example 5 for the combined use of ethyl benzoyl acetate and meropenem in the mature biofilm model. DETAILED DESCRIPTION

[0029] The following describes the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the illustrations provided in the following embodiments only illustrate the basic concept of the present invention in a schematic manner, and the following embodiments and features in the embodiments can be combined with each other without conflict.

[0030] Example 1

[0031] The ethyl benzoyl acetate emulsion was prepared as follows:

[0032] (1) Accurately pipette 86 μL of ethyl benzoyl acetate (96 mg) and 100 μL of Tween 80, dissolve in 1814 μL of ethanol, and transfer to a 50 mL eggplant-shaped bottle after thorough sonication;

[0033] (2) The above eggplant-shaped bottle was placed in a constant temperature water bath at 45° C. and subjected to rotary evaporation for 5 min to fully dry the organic solvent ethanol, 1814 μL of sterile water was added to the eggplant-shaped bottle, and the inner wall of the eggplant-shaped bottle was fully blown with a gun tip to fully dissolve ethyl benzoyl acetate in the water phase to obtain a mixed solution;

[0034] (3) The mixed solution was transferred to an EP tube and filtered through a 0.22 μM sterile filter to obtain a uniform milky white ethyl benzoyl acetate emulsion with a concentration of 48 mg / mL. Figure 1 As shown, A is the appearance of the solvent and B is the appearance of the ethyl benzoyl acetate emulsion.

[0035] Example 2

[0036] The antibacterial and membrane-destroying activities of ethyl benzoyl acetate are investigated as follows:

[0037] 1. Drug sensitivity test: Determine the minimum inhibitory concentration of ethyl benzoyl acetate against strongly film-forming Klebsiella pneumoniae (KP 2127).

[0038] (1) Activation of strains: Wear a mask, hat, gloves and white coat, and operate in the sterile environment of a biosafety cabinet. Transfer 100 μL of KP 2127 bacterial solution and quality control bacteria E. coli ATCC 25922 stored in a -80°C refrigerator to a sterile shaking tube containing 2 mL of LB medium, and culture in a constant temperature shaker at 190 rpm and 37°C for 6 to 8 h; use a disposable sterile inoculation loop to pick up the culture solution and streak it in three zones on a MacConkey agar plate, place it in a constant temperature shaker at 190 rpm and 37°C for overnight culture, and obtain a plate with the corresponding activated strain.

[0039] (2) Determination of minimum inhibitory concentration: Use a sterile inoculation loop to pick a single colony (of appropriate size and in a straight line) from the plate of the corresponding activated strain, rinse it repeatedly in a sterile shaking tube containing 5 mL of sterile LB medium, discard the inoculation loop, mark the operator, strain number and time, and culture it in a constant temperature shaker at 190 rpm and 37°C for 5 to 6 h until the McFarland turbidity unit is about 0.5, so that the bacteria are in the logarithmic growth phase, and use sterile MHB medium to dilute the bacterial solution 1000 times to obtain a 1000-fold diluted suspension for use;

[0040] First, add 75 μL of a thousand-fold diluted suspended bacterial solution to columns 2 to 8 of a pointed-bottom 96-well plate; first add 30 μL of the 48 mg / mL ethyl benzoyl acetate emulsion prepared in Example 1 to the first column (thaw and shake well before use), then add 120 μL of a thousand-fold diluted suspended bacterial solution, and mix again by pipetting; aspirate 75 μL of the solution in the first column and add it to the second column, and mix and blow evenly with the 75 μL of a thousand-fold diluted suspended bacterial solution added in advance; aspirate 75 μL of the solution in the second column and add it to the third column, and mix and blow evenly with the 75 μL of a thousand-fold diluted suspended bacterial solution added in advance; aspirate 75 μL of the solution in the third column and add it to the fourth column, and mix and blow evenly with the 75 μL of a thousand-fold diluted suspended bacterial solution added in advance; aspirate 75 μL of the solution in the fourth column and add it to the fifth column, and mix and blow evenly with the 75 μL of a thousand-fold diluted suspended bacterial solution added in advance; aspirate 75 μL of the solution in the fourth column and add it to the fifth column, and mix and blow evenly with the 75 μL of a thousand-fold diluted suspended bacterial solution added in advance; Add the solution in the fifth column to the sixth column, and mix it with 75μL of the thousand-fold diluted suspended bacterial solution added in advance, and blow it evenly; aspirate 75μL of the solution in the sixth column and add it to the seventh column, and mix it with 75μL of the thousand-fold diluted suspended bacterial solution added in advance, and blow it evenly; aspirate 75μL of the solution in the seventh column and add it to the eighth column, and mix it with 75μL of the thousand-fold diluted suspended bacterial solution added in advance, and blow it evenly; aspirate 75μL of the solution in the eighth column and add it to the ninth column, and mix it with 75μL of the thousand-fold diluted suspended bacterial solution added in advance, and blow it evenly; aspirate 75μL of the solution in the ninth column and add it to the tenth column, and mix it with 75μL of the thousand-fold diluted suspended bacterial solution added in advance, and blow it evenly; aspirate 75μL of the solution in the tenth column and add it to the 75μL of the thousand-fold diluted suspended bacterial solution added in advance to the eleventh column, and blow it evenly, discard 75μL, and add 75μL of the thousand-fold diluted suspended bacterial solution to the twelfth column as a positive control. The 96-well plate was sealed with plastic wrap and placed in a 37°C incubator for 16 to 20 hours. The drug concentration in the first well without turbidity from column 12 onwards was the minimum inhibitory concentration (MIC) of the drug against the bacteria. The results were determined according to CLSI (2020) and the MIC values ​​were recorded. All experiments were repeated three times.

[0041] 2. Crystal violet experiment

[0042] Use a sterile inoculation loop to pick a single colony (of appropriate size and in a straight line) from the plate of the corresponding strain for activation, rinse it repeatedly in a sterile shaking tube containing 5 mL of sterilized TSB medium, discard the inoculation loop, mark the operator, strain number and time, and culture it overnight in a constant temperature shaker at 190 rpm and 37°C until the OD after two-fold dilution is 0. 600 = about 0.5, use sterilized TSB medium to dilute the bacterial solution 40 times and set aside.

[0043] Inoculate in a sterile 96-well plate at a density of 200 μL / well, add sterile water and blank TSB medium (to prevent drying and check for contamination) around the 96-well plate, place in a 37°C incubator overnight for 24 hours, and replace the medium every 12 hours. Remove the medium containing planktonic bacteria and gently rinse three times with sterile PBS to obtain a mature biofilm model.

[0044] The ethyl benzoyl acetate emulsion prepared in Example 1 at a concentration of 48 mg / mL was diluted in sequence with blank TSB to obtain ethyl benzoyl acetate emulsions with final concentrations of 0 MIC, 0.125 MIC, 0.25 MIC, 0.5 MIC, 1 MIC, and 2 MIC (TSB ratio was consistent), and added to the biofilm model at a standard of 200 μL / well, and the cells were incubated at 37°C for 12 h before crystal violet staining.

[0045] Remove the culture medium containing planktonic bacteria, gently rinse three times with sterile PBS, fix with methanol and dry, add 150 μL 0.1% (m / v) CV to each well, stain for 30 min, remove the dye, use first-class water to remove the unadsorbed dye, add 150 μL 33% (v / v) acetic acid solution to each well for elution, and detect OD on an enzyme reader 580 , all experiments were repeated three times.

[0046] Example 3

[0047] The effect of ethyl benzoyl acetate on the destruction of the membrane was investigated. The specific method is as follows:

[0048] 1. Scanning electron microscopy observation of ethyl benzoyl acetate destroying biofilm

[0049] Use a sterile inoculation loop to pick a single colony (of appropriate size and in a straight line) from the plate of the corresponding strain for activation, rinse it repeatedly in a sterile shaking tube containing 5 mL of sterilized TSB medium, discard the inoculation loop, mark the operator, strain number and time, and culture it overnight in a constant temperature shaker at 190 rpm and 37°C until the OD after two-fold dilution is 600 = about 0.5, use sterilized TSB medium to dilute the bacterial solution 40 times and set aside.

[0050] Inoculate in a 12-well plate with 1.5 mL / well, place a 9 mm diameter cell slide, and set up a control group and a drug-treated group. Place in a 37°C incubator for overnight culture for 24 hours, and replace the culture medium every 12 hours. Remove the culture medium containing planktonic bacteria, gently rinse three times with sterile PBS, and obtain a mature biofilm model. Dilute the 48 mg / mL ethyl benzoyl acetate emulsion prepared in Example 1 with TSB culture medium to a final concentration of 0.25 MIC, add it to the biofilm model at a standard of 1.5 mL / well, and after static culture at 37°C for 12 hours, remove the culture medium containing planktonic bacteria, transfer the cell slide to a new 12-well plate, add a 4% mass concentration of glutaraldehyde solution and a 2% mass concentration of paraformaldehyde solution to each well for overnight fixation to obtain a fixative.

[0051] The sample was taken out from the fixing solution and dehydrated in ethanol gradient with volume concentrations of 50%, 70%, and 100% in sequence. Each concentration was dehydrated for 10 minutes. After dehydration, the sample was taken out from the ethanol with a volume concentration of 100% and placed in a supercritical dryer for critical point drying. The drying time was about 1 hour. After drying, the sample was taken out from the sample chamber of the critical point dryer, fixed on the sample stage with conductive tape, sprayed with gold, and tested.

[0052] 2. Confocal microscopy observation of ethyl benzoyl acetate's destruction of the three-dimensional structure of biofilm

[0053] Use a sterile inoculation loop to pick a single colony (of appropriate size and in a straight line) from the plate of the corresponding strain for activation, rinse it repeatedly in a sterile shaking tube containing 5 mL of sterilized TSB medium, discard the inoculation loop, mark the operator, strain number and time, and culture it overnight in a constant temperature shaker at 190 rpm and 37°C until the OD after two-fold dilution is 0. 600 = about 0.5, use sterilized TSB medium to dilute the bacterial solution 40 times and set aside.

[0054] The confocal dish was inoculated with a standard of 1.5 mL / well and placed in an incubator at 37°C for overnight culture for 24 hours, with the culture medium replaced every 12 hours. The culture medium containing planktonic bacteria was removed and gently rinsed three times with sterile PBS to obtain a mature biofilm model. The 48 mg / mL ethyl benzoyl acetate stock solution prepared in Example 1 was diluted with TSB culture medium to a final concentration of 0.25 MIC, and added to the biofilm model at 1.5 mL / well. After static culture at 37°C for 12 hours, the culture medium containing planktonic bacteria was removed and SYTO 9 / PI staining was performed.

[0055] Prepare fluorescent stain working solution by adding 3 μL SYTO 9 and 3 μL PI to 1 mL of filtered sterilized water. Immediately and gently add 500 μL of stain solution to the biofilm sample before the biofilm dries, incubate at room temperature for 20-30 minutes, rinse the sample gently with sterilized PBS, remove all excess stain, add 500 μL of sterilized PBS solution to each confocal dish, and complete the shooting on the laser confocal ultra-high-speed dual-disc live cell real-time dynamic imaging system.

[0056] 3. Rheological experiment

[0057] Use a sterile inoculation loop to pick a single colony (of appropriate size and in a straight line) from the plate of the corresponding strain for activation, rinse it repeatedly in a sterilized 50 mL EP tube containing 15 mL of sterilized TSB medium, discard the inoculation loop, mark the operator, strain number and time, and culture it overnight in a constant temperature shaker at 190 rpm and 37°C until the OD after two-fold dilution reaches 0. 600 = about 0.5, use sterilized TSB medium to dilute the bacterial solution 40 times and set aside.

[0058] Inoculate 80 mL / dish in a large culture dish, culture it statically in a 37°C incubator for 24 hours, replace the culture medium every 12 hours, remove the culture medium containing planktonic bacteria, and obtain a membrane model. Dosing group: dilute the 48 mg / mL ethyl benzoyl acetate stock solution prepared in Example 1 with TSB culture medium to a final concentration of 0.5 MIC, and add 80 mL / dish to the membrane model. Control group: dilute with sterile PBS equal to the volume of ethyl benzoyl acetate and an equal amount of blank TSB culture medium, and add 80 mL / dish to the membrane model. Culture it statically at 37°C for 12 hours. Use 2 large culture dishes for each group, use a cell scraper to scrape the biofilm sample, and send the sample to measure its viscosity curve at different shear rates.

[0059] Example 4

[0060] The mechanism of ethyl benzoyl acetate destroying the membrane was investigated. The specific method is as follows:

[0061] 1. Phenol-sulfuric acid method

[0062] According to the experimental method in Example 2, a mature biofilm model of a 12-well plate was obtained, and the 48 mg / mL ethyl benzoyl acetate emulsion prepared in Example 1 was diluted with blank TSB to a final concentration of 0 MIC, 0.125 MIC, 0.25 MIC, 0.5 MIC, 1 MIC, and 2 MIC (TSB ratio was consistent), and 1.5 mL / well was added to the biofilm model, and cultured at 37°C for 12 h. The level of extracellular polysaccharides in the biofilm was determined by the phenol-sulfuric acid method, and the specific operation was as follows:

[0063] Prepare a standard glucose solution with a concentration of 0.2 mg / mL, add 0, 6.25, 12.5, 25, 50, 75, 100 μL of the prepared standard glucose solution to 1.5 mL EP tubes, and add first-grade water to each tube to make it up to 100 μL. Add 100 μL of 0.5% (v / v) phenol solution to each tube, mix quickly, and then add 500 μL of concentrated sulfuric acid. After leaving it at room temperature for 20 minutes, use an enzyme reader to detect the OD 485 , draw the standard curve.

[0064] After removing the culture medium containing planktonic bacteria, gently wash three times with PBS, add 100 μL PBS to each well, blow repeatedly, and properly ultrasonically elute the biofilm, transfer to a 1.5 mL EP tube, add 100 μL of 0.5% phenol solution to each tube, quickly mix, add 500 μL concentrated sulfuric acid, leave at room temperature for 20 minutes, and detect OD by microplate reader 485 , the polysaccharide concentration of the sample was calculated according to the standard curve.

[0065] 2. Phenol-chloroform-isoamyl alcohol method

[0066] According to the experimental method in Example 2, a mature biofilm model of a 12-well plate was obtained. The 48 mg / mL ethyl benzoyl acetate emulsion prepared in Example 1 was diluted to a final concentration of 0 MIC, 0.125 MIC, 0.25 MIC, 0.5 MIC, 1 MIC, and 2 MIC (TSB ratio was consistent) with blank TSB in turn, and 1.5 mL / well was added to the biofilm model and cultured at 37°C for 12 h. The extracellular DNA of the biofilm was extracted and purified by the phenol-chloroform-isoamyl alcohol method, and the extracellular DNA level was measured by a nucleic acid quantifier. The specific extraction operation is as follows:

[0067] 450 μL 0.5 M EDTA-2Na was added to each well of a 12-well plate, and the culture medium containing planktonic bacteria was removed after being placed at 4°C for 1 h; 70 μL TEN buffer was added to each well, the membrane was resuspended and then transferred to an EP tube and centrifuged (1200 r / min, 5 min); the supernatant was aspirated to a new EP tube, mixed with 300 μL TE buffer, and a mixed solution of phenol, chloroform and isoamyl alcohol (wherein the volume ratio of phenol, chloroform and isoamyl alcohol was 25:24:1) was added and centrifuged (1200 r / min, 10 min); the supernatant was aspirated to a new EP tube, 3 volumes of pre-cooled pure ethanol and a final concentration of 10% 3M sodium acetate were added, and the mixture was placed at -20°C overnight; the supernatant was discarded after centrifugation at 4°C (1400 r / min, 30 min); the precipitate was washed with 70% cold ethanol and then allowed to air dry, 20 μL TE buffer was added to each tube to dissolve, and the purity and nucleic acid concentration were determined by a nucleic acid quantifier.

[0068] 3. BCA method

[0069] According to the experimental method in Example 2, a mature biofilm model of a 96-well plate was obtained, and the 48 mg / mL ethyl benzoyl acetate stock solution prepared in Example 1 was diluted with blank TSB to a final concentration of 0 MIC, 0.125 MIC, 0.25 MIC, 0.5 MIC, 1 MIC, and 2 MIC (TSB ratio was consistent), and added to the biofilm model at a standard of 200 μL / well, and cultured at 37°C for 12 hours. The extracellular protein level of the biofilm was determined by the BCA method, and the specific operation was as follows:

[0070] Add 0μL, 1μL, 2μL, 4μL, 8μL, 12μL, 16μL, and 20μL of standard protein to the standard wells of the 96-well plate, add standard diluent to make up to 20μL, add 200μL BCA working solution to each well, place at 37℃ for 20-30min, and measure OD with an enzyme-labeled instrument. 562 .

[0071] After removing the culture medium containing planktonic bacteria, gently wash three times with PBS, add 20 μL PBS to each well, repeatedly blow and ultrasonically wash the biofilm, add 180 μL BCA working solution (prepare an appropriate amount of BCA working solution according to 50 volumes of BCA reagent A plus 1 volume of BCA reagent B (i.e., the volume ratio of BCA reagent A to BCA reagent B is 50:1) and mix well), incubate at 37°C for 20 minutes, and measure OD with an enzyme reader 562 , the protein concentration of the sample was calculated based on the standard curve.

[0072] Example 5

[0073] The combined effect of ethyl benzoyl acetate and meropenem was investigated. The specific method is as follows:

[0074] 1. Chessboard method

[0075] Use a sterile inoculation loop to pick up a single colony (of appropriate size and in a straight line) from the plate of the corresponding activated strain, rinse it repeatedly in a sterile shaking tube containing 5 mL of sterilized TSB medium, discard the inoculation loop, mark the operator, strain number and time, and culture it in a constant temperature shaker at 190 rpm and 37°C for 5 to 6 hours until the McFarland turbidity unit is about 0.5, so that the bacteria are in the logarithmic growth phase, and use sterilized MHB medium to dilute the bacterial solution 1000 times as the working bacterial solution for use.

[0076] A 96-well sterile microplate was used, with 4 times the MIC as the first well concentration, and 8 dilutions were taken to prepare the meropenem stock solution and the 48 mg / mL ethyl benzoyl acetate stock solution prepared in Example 1, which was diluted to a concentration of 8 MIC using the above working bacterial solution, and arranged on the rows and columns of the plate, respectively, and the rows and columns were diluted with the working bacterial solution; the ethyl benzoyl acetate and meropenem diluted in multiples were fully mixed to the left side of the same well plate (8×8); the MIC of ethyl benzoyl acetate and meropenem were measured on the right side of the well plate, respectively, and the wells were wrapped and sealed with plastic wrap, and cultured at 37°C for 16 to 24 hours; the results were read, and the partial inhibitory concentration index (FIC) was calculated according to the following formula to determine the interaction between ethyl benzoyl acetate and clinical antibacterial drugs. When FIC≤0.5, a synergistic effect occurs, when 0.5<FIC≤1, an additive effect occurs, when 1<FIC≤2, there is no effect, and when FIC>2, an antagonistic effect occurs.

[0077]

[0078] 2. Resazurin Method

[0079] According to the experimental method in Example 2, a mature biofilm model of a 96-well plate was obtained, and the 48 mg / mL ethyl benzoyl acetate stock solution prepared in Example 1 was diluted to a final concentration of 0.5 MIC and MIC using blank TSB, and the 10.24 mg / mL meropenem stock solution was diluted to a final concentration of 2 MIC and 4 MIC using blank TSB. EBA group: TSB medium containing ethyl benzoyl acetate at a final concentration of 0.5 MIC was added to the biofilm model at 200 μL / well; control group: blank TSB; MEM group: TSB medium containing meropenem at a final concentration of 2 MIC was added to the biofilm model at 200 μL / well; EBA+MEM group: TSB medium containing meropenem at a final concentration of 4 MIC was added to the biofilm model at 200 μL / well, and TSB medium containing ethyl benzoyl acetate at a final concentration of MIC was added to the biofilm model at 100 μL / well, and the mixture was fully mixed and then cultured at 37°C for 12 hours.

[0080] Prepare 1.5 mg / mL resazurin stock solution and dilute to 150 μg / mL with sterile water. Transfer 90 μL of each well in the 96-well plate model of the above system to a new black 96-well plate, add 10 μL of 150 μg / mL resazurin solution to each well, mix thoroughly, incubate at 37°C for 20 minutes, and measure the fluorescence (530 nm, 590 nm). The fluorescence value of the control group is converted to obtain the percentage of inhibition of each treatment group.

[0081] Figure 2 The results of the drug sensitivity test of ethyl benzoyl acetate in Example 2 are shown in Table 2. Figure 2It can be seen that when the inhibitory concentration of ethyl benzoylacetate is ≥2.4 mg / mL, the corresponding inhibitory effect can be achieved on both the standard strain and the strong film-forming strain. Therefore, it can be seen that the minimum inhibitory concentration of ethyl benzoylacetate for the standard strain and the strong film-forming strain is 2.4 mg / mL.

[0082] Figure 3 The crystal violet test result of ethyl benzoyl acetate in Example 2. Figure 3 It can be seen that when the concentration of ethyl benzoyl acetate is 0.25 times the MIC, i.e. 0.6 mg / mL, the membrane can be destroyed. Therefore, the minimum concentration of ethyl benzoyl acetate that can destroy the membrane is 0.25 times the MIC, i.e. 0.6 mg / mL.

[0083] Figure 4 The crystal violet staining results of ethyl benzoyl acetate treated at different times in Example 2. Figure 4 It can be seen that when the concentration of ethyl benzoyl acetate is 0.5 times MIC and 0.25 times MIC, the trend of biofilm destruction is consistent, and both reach the best biofilm destruction effect at 8 hours, but the effect of 0.5 times MIC group is better than that of 0.25 times MIC group. It can be seen that the concentration of ethyl benzoyl acetate to destroy biofilm is 0.25MIC~0.5MIC (i.e. 0.6~1.2mg / mL).

[0084] Figure 5 The visualization results of the biofilm before and after the action of ethyl benzoyl acetate in Example 3, wherein A is a scanning electron microscope and B is a laser confocal microscope plan view after SYTO9 / PI staining. Figure 5 It can be seen that the PBS treatment group was used as the control group (Control) and the 0.6 mg / mL ethyl benzoyl acetate emulsion was used as the treatment group (EBA). The control group (Control) formed a dense biofilm, and the filaments clearly contained a large number of live bacteria inside. In the treatment group (EBA), after being treated with ethyl benzoyl acetate, the extracellular filaments in the biofilm matrix were significantly reduced, the biofilm biomass was reduced, and the bacterial activity in the biofilm decreased. This shows that ethyl benzoyl acetate can indeed destroy the biofilm.

[0085] Figure 6 The viscosity curves of the biofilm before and after the action of ethyl benzoyl acetate in Example 3 are shown in FIG. Figure 6 It can be seen that the viscosity of the biofilm was significantly reduced and the mechanical stability decreased after treatment with ethyl benzoyl acetate.

[0086] Figure 7 The results of the effect of ethyl benzoyl acetate on extracellular proteins of biofilm in Example 4, where A is the standard protein curve and B is the measurement result. Figure 7It can be seen that the extracellular protein content in the extracellular matrix was significantly reduced after treatment with ethyl benzoyl acetate, and the amount of extracellular protein reduction increased with the increase of ethyl benzoyl acetate concentration.

[0087] Figure 8 The results of the effect of ethyl benzoyl acetate on the extracellular polysaccharide of biofilm in Example 4, where A is the standard glucose curve and B is the measurement result. Figure 8 It can be seen that the content of extracellular polysaccharides in the extracellular matrix was significantly reduced after treatment with ethyl benzoyl acetate, and the reduction amount of extracellular polysaccharides increased with the increase of ethyl benzoyl acetate concentration.

[0088] Fig. 9 The results of the effect of ethyl benzoyl acetate on extracellular DNA in biofilms in Example 4 are shown in Table 1. Fig. 9 It can be seen that when the concentration of ethyl benzoyl acetate is ≤MIC, there is no significant effect on the level of extracellular DNA in the extracellular matrix of the biofilm; when the concentration is greater than MIC, the level of extracellular DNA increases, which is considered to be caused by the release of intracellular DNA due to bacterial rupture.

[0089] Fig.10 The FICI results of the chessboard method for the combined use of ethyl benzoyl acetate and meropenem in the 8 strains tested in Example 5 are shown in Table 1. Fig.10 It can be seen that ethyl benzoylacetate and meropenem exhibit synergistic antibacterial effects in multiple strong film-forming strains, indicating that ethyl benzoylacetate of the present invention can be used in combination with the antibiotic meropenem to destroy biofilms.

[0090] Fig.11 The results of the combination of ethyl benzoyl acetate and meropenem in the mature biofilm model in Example 5 are shown in Table 1. Fig.11 It can be seen that the ethyl benzoyl acetate emulsion with a concentration of 0.5 times the MIC and the meropenem solution with a concentration of 2 times the MIC alone have no obvious antibacterial effect in the mature biofilm model, but the antibacterial percentage of the two combined administration at the same concentration is about 75%. It can be seen that the ethyl benzoyl acetate of the present invention can be used in combination with the antibiotic meropenem to enhance the antibacterial effect.

[0091] Similarly, when "Klebsiella pneumoniae" in the above performance test is replaced with "Escherichia coli" or "Salmonella", the performance test results are similar to the above effect on Klebsiella pneumoniae, proving that the ethyl benzoyl acetate of the present invention can indeed destroy mature biofilms such as Klebsiella pneumoniae, Escherichia coli, and Salmonella.

[0092] In summary, the present invention discloses the application of ethyl benzoylacetate in destroying the activity of mature biofilms. Ethyl benzoylacetate is used as an anti-biofilm compound, which has the ability to efficiently destroy mature biofilms at sub-inhibitory concentrations, and can significantly reduce the levels of macromolecules such as extracellular proteins and extracellular polysaccharides in the extracellular matrix. In addition, ethyl benzoylacetate reduces the level of macromolecules in the extracellular matrix of mature biofilms, causing the collapse of the three-dimensional structure of the biofilm, thereby significantly improving the therapeutic effect of biofilm infection.

[0093] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. Application of ethyl benzoyl acetate in destroying the activity of mature biofilm.

2. The use according to claim 1, It is characterized in that In the application, ethyl benzoyl acetate, Tween 80 and sterile water are used to prepare an oil-in-water emulsion.

3. The use according to claim 2, It is characterized in that The volume ratio of ethyl benzoyl acetate, Tween 80 and sterile water in the oil-in-water emulsion is 86:100-200:1714-1814.

4. The use according to claim 1, It is characterized in that In the application, ethyl benzoyl acetate reduces the content of extracellular polysaccharides and extracellular proteins in the extracellular matrix of mature bacterial biofilms, thereby causing the three-dimensional structure of the bacterial biofilm to collapse.

5. The use according to claim 1, It is characterized in that The mature biofilm includes but is not limited to any one of Klebsiella pneumoniae, Escherichia coli or Salmonella.

6. The use according to claim 1, It is characterized in that The application also includes combined use with antibacterial drugs.

7. The use according to claim 6, It is characterized in that The antibacterial drugs include any one or more of tetracycline, meropenem or ceftriaxone sodium.